Longevity & AgingNew Dyslipidaemia Guide Reveals Why Most High-Risk Patients Miss LDL Targets
Despite effective therapies, dyslipidaemia remains massively undertreated. In Germany, only 27% of ASCVD patients managed by cardiologists and ~12% managed by GPs achieve the guideline LDL-C target of under 55 mg/dL. This 2026 review from leading German and European cardiologists synthesizes current evidence on lipid biomarkers—LDL-C, ApoB, Lp(a), triglycerides, and remnant cholesterol—and provides practical diagnostic and therapeutic guidance. It incorporates the 2025 ESC/EAS Focused Update, highlighting two key new recommendations: accounting for cardiovascular risk modifiers like Lp(a) and CRP, and using potent early combination lipid-lowering therapy after acute coronary syndrome. Statins remain first-line, with ezetimibe, bempedoic acid, and PCSK9 inhibitors as add-ons. Novel RNA-based therapies are on the horizon.
